| Publications | PubMed=4369887; DOI=10.1073/pnas.71.8.3283
Klein G., Lindahl T., Jondal M., Leibold W., Menezes J., Nilsson K., Sundstrom C.
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.
Proc. Natl. Acad. Sci. U.S.A. 71:3283-3286(1974) PubMed=171663; DOI=10.1073/pnas.72.9.3518
Steinitz M., Klein G.
Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro.
Proc. Natl. Acad. Sci. U.S.A. 72:3518-3520(1975) PubMed=179629
Menezes J., Leibold W., Klein G., Clements G.B.
Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.
Biomedicine 22:276-284(1975) PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980) PubMed=6286763
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982) PubMed=6600440; DOI=10.1007/BF02617996
Uittenbogaart C.H., Cantor Y., Fahey J.L.
Growth of human malignant lymphoid cell lines in serum-free medium.
In Vitro 19:67-72(1983) PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984) PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=3495441; DOI=10.1002/eji.1830170503
Kanowith-Klein S., Saxon A., Uittenbogaart C.H.
Constitutive production of B cell differentiation factor-like activity by human T and B cell lines.
Eur. J. Immunol. 17:593-598(1987) PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991) PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993) PubMed=8515068
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993) PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996) PubMed=23292937; DOI=10.1073/pnas.1205299110
Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C., Naresh K., Evens A., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013) PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015) PubMed=29416618; DOI=10.18632/oncotarget.20378
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S., Shen C., Young K.H., Westin J., Davis R.E., Hu S., Medeiros L.J., Ford R.J., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018) PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S., Pogue E., Ding Z., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018) PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020
Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D., Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P., Lossos I.S., Landgraf R., Vega F.
Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology.
Cancer Lett. 436:149-158(2018) PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019) |
|---|